Jpmorgan Chase & CO Corbus Pharmaceuticals Holdings, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.11 - $5.46 $61 - $3,052	-559 Reduced 1.27%	43,415 $5,000
Q3 2022 Nov 14, 2022	SELL	$0.17 - $5.31 $1,649 - $51,517	-9,702 Reduced 18.08%	43,974 $7,000
Q2 2022 Aug 11, 2022	SELL	$0.21 - $0.53 $10,388 - $26,218	-49,469 Reduced 47.96%	53,676 $14,000
Q1 2022 May 11, 2022	SELL	$0.32 - $0.67 $1,422 - $2,978	-4,445 Reduced 4.13%	103,145 $55,000
Q4 2021 Feb 10, 2022	BUY	$0.6 - $1.11 $43,804 - $81,038	73,008 Added 211.12%	107,590 $66,000
Q3 2021 Nov 12, 2021	BUY	$1.01 - $1.82 $34,927 - $62,939	34,582 New	34,582 $35,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.